Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maxcyte (MXCT) Total Current Liabilities (2020 - 2026)

Maxcyte has reported Total Current Liabilities over the past 6 years, most recently at $14.3 million for Q4 2025.

  • Quarterly Total Current Liabilities fell 9.56% to $14.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $14.3 million through Dec 2025, down 9.56% year-over-year, with the annual reading at $14.3 million for FY2025, 9.56% down from the prior year.
  • Total Current Liabilities was $14.3 million for Q4 2025 at Maxcyte, down from $16.1 million in the prior quarter.
  • Over five years, Total Current Liabilities peaked at $18.1 million in Q2 2022 and troughed at $11.6 million in Q2 2025.
  • The 5-year median for Total Current Liabilities is $15.5 million (2022), against an average of $15.0 million.
  • Year-over-year, Total Current Liabilities skyrocketed 44.46% in 2022 and then fell 27.08% in 2023.
  • A 5-year view of Total Current Liabilities shows it stood at $15.6 million in 2021, then fell by 1.22% to $15.4 million in 2022, then rose by 15.74% to $17.9 million in 2023, then decreased by 11.65% to $15.8 million in 2024, then fell by 9.56% to $14.3 million in 2025.
  • Per Business Quant, the three most recent readings for MXCT's Total Current Liabilities are $14.3 million (Q4 2025), $16.1 million (Q3 2025), and $11.6 million (Q2 2025).